Suppr超能文献

通过多分析物血液检测对外科可切除癌症进行检测和定位。

Detection and localization of surgically resectable cancers with a multi-analyte blood test.

作者信息

Cohen Joshua D, Li Lu, Wang Yuxuan, Thoburn Christopher, Afsari Bahman, Danilova Ludmila, Douville Christopher, Javed Ammar A, Wong Fay, Mattox Austin, Hruban Ralph H, Wolfgang Christopher L, Goggins Michael G, Dal Molin Marco, Wang Tian-Li, Roden Richard, Klein Alison P, Ptak Janine, Dobbyn Lisa, Schaefer Joy, Silliman Natalie, Popoli Maria, Vogelstein Joshua T, Browne James D, Schoen Robert E, Brand Randall E, Tie Jeanne, Gibbs Peter, Wong Hui-Li, Mansfield Aaron S, Jen Jin, Hanash Samir M, Falconi Massimo, Allen Peter J, Zhou Shibin, Bettegowda Chetan, Diaz Luis A, Tomasetti Cristian, Kinzler Kenneth W, Vogelstein Bert, Lennon Anne Marie, Papadopoulos Nickolas

机构信息

Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

出版信息

Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.

Abstract

Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was greater than 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.

摘要

早期检测是降低癌症死亡率的关键。在此,我们描述了一种血液检测方法,该方法可通过评估循环蛋白水平和游离DNA中的突变来检测八种常见癌症类型。我们将这种名为CancerSEEK的检测方法应用于1005例患有非转移性、临床检测出的卵巢癌、肝癌、胃癌、胰腺癌、食管癌、结直肠癌、肺癌或乳腺癌的患者。CancerSEEK检测在八种癌症类型中,中位阳性率为70%。对于五种没有针对一般风险个体的筛查检测的癌症类型(卵巢癌、肝癌、胃癌、胰腺癌和食管癌),检测敏感性范围为69%至98%。CancerSEEK的特异性大于99%:812名健康对照中只有7人检测呈阳性。此外,在中位83%的患者中,CancerSEEK将癌症定位到少数解剖部位。

相似文献

2
Assessing aneuploidy with repetitive element sequencing.利用重复元件测序评估非整倍体。
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4858-4863. doi: 10.1073/pnas.1910041117. Epub 2020 Feb 19.

引用本文的文献

8
The coming era of proteomics-driven precision medicine.蛋白质组学驱动的精准医学时代即将来临。
Natl Sci Rev. 2025 Jul 14;12(8):nwaf278. doi: 10.1093/nsr/nwaf278. eCollection 2025 Aug.
10
Liquid biopsy in lung cancer.肺癌的液体活检
Breathe (Sheff). 2025 Aug 19;21(3):250051. doi: 10.1183/20734735.0051-2025. eCollection 2025 Jul.

本文引用的文献

3
Predicting treatment resistance and relapse through circulating DNA.通过循环 DNA 预测治疗抵抗和复发。
Breast. 2017 Aug;34 Suppl 1:S31-S35. doi: 10.1016/j.breast.2017.06.024. Epub 2017 Jul 8.
8
Liquid Biopsies, What We Do Not Know (Yet).液体活检,未解之谜。
Cancer Cell. 2017 Feb 13;31(2):172-179. doi: 10.1016/j.ccell.2017.01.002.
9
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
10
COSMIC: somatic cancer genetics at high-resolution.COSMIC:高分辨率体细胞癌遗传学
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783. doi: 10.1093/nar/gkw1121. Epub 2016 Nov 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验